Back to top
more

MDxHealth SA (MDXH)

(Real Time Quote from BATS)

$2.79 USD

2.79
66,294

+0.04 (1.46%)

Updated Aug 7, 2025 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MDxHealth SA (MDXH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA (MDXH) delivered earnings and revenue surprises of -15.38% and +0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA (MDXH) delivered earnings and revenue surprises of -46.15% and 0.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of 20% and 16.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Outset Medical (OM) delivered earnings and revenue surprises of -234.02% and 7.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH)

by Zacks Equity Research

MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA (MDXH) delivered earnings and revenue surprises of 30% and 7.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agiliti (AGTI) Q4 Earnings Beat Estimates

by Zacks Equity Research

Agiliti (AGTI) delivered earnings and revenue surprises of 8.33% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -3.70% and 3.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris (VTRS) Beats Q3 Earnings Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 5.41% and 1.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Pediatrix Medical Group (MD) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -25.58% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 6.25% and 10.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cano Health, Inc. (CANO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cano Health, Inc. (CANO) delivered earnings and revenue surprises of -211.11% and 8.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMN Healthcare Services (AMN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 10.70% and 0.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 87.50% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PerkinElmer (PKI) Q1 Earnings Surpass Estimates

by Zacks Equity Research

PerkinElmer (PKI) delivered earnings and revenue surprises of 2.02% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMN Healthcare Services (AMN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 5.51% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Premier, Inc. (PINC) Q3 Earnings Match Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 0% and 8.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: MDxHealth SA Sponsored ADR (MDXH) Q1 Earnings Expected to Decline

by Zacks Equity Research

MDxHealth SA Sponsored ADR (MDXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Elevance (ELV) to Divest Life & Disability Business to StanCorp

by Zacks Equity Research

With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.

Zacks Equity Research

Is a Surprise Coming for MDxHealth (MDXH) This Earnings Season?

by Zacks Equity Research

MDxHealth (MDXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.